These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antibiotic Resistance in Pseudomonas. Laborda P; Hernando-Amado S; Martínez JL; Sanz-García F Adv Exp Med Biol; 2022; 1386():117-143. PubMed ID: 36258071 [TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa: a clinical and genomics update. Pelegrin AC; Palmieri M; Mirande C; Oliver A; Moons P; Goossens H; van Belkum A FEMS Microbiol Rev; 2021 Nov; 45(6):. PubMed ID: 33970247 [TBL] [Abstract][Full Text] [Related]
4. The Small RNA ErsA Plays a Role in the Regulatory Network of Pseudomonas aeruginosa Pathogenicity in Airway Infections. Ferrara S; Rossi A; Ranucci S; De Fino I; Bragonzi A; Cigana C; Bertoni G mSphere; 2020 Oct; 5(5):. PubMed ID: 33055260 [TBL] [Abstract][Full Text] [Related]
5. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Smith S; Ratjen F; Remmington T; Waters V Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092 [TBL] [Abstract][Full Text] [Related]
6. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280 [TBL] [Abstract][Full Text] [Related]
7. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972 [TBL] [Abstract][Full Text] [Related]
8. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986 [TBL] [Abstract][Full Text] [Related]
9. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Smith S; Waters V; Jahnke N; Ratjen F Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436 [TBL] [Abstract][Full Text] [Related]
10. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277 [TBL] [Abstract][Full Text] [Related]
11. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis. Stefani S; Campana S; Cariani L; Carnovale V; Colombo C; Lleo MM; Iula VD; Minicucci L; Morelli P; Pizzamiglio G; Taccetti G Int J Med Microbiol; 2017 Sep; 307(6):353-362. PubMed ID: 28754426 [TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters. Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275 [TBL] [Abstract][Full Text] [Related]
14. Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in Jorth P; McLean K; Ratjen A; Secor PR; Bautista GE; Ravishankar S; Rezayat A; Garudathri J; Harrison JJ; Harwood RA; Penewit K; Waalkes A; Singh PK; Salipante SJ mBio; 2017 Oct; 8(5):. PubMed ID: 29089424 [TBL] [Abstract][Full Text] [Related]
15. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT. Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975 [TBL] [Abstract][Full Text] [Related]
16. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study. Millar BC; Rendall JC; Downey DG; Moore JE J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786 [TBL] [Abstract][Full Text] [Related]
17. Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis. López-Causapé C; Oliver A Future Microbiol; 2017 Dec; 12():1445-1448. PubMed ID: 29068237 [No Abstract] [Full Text] [Related]
18. NtrBC Selectively Regulates Host-Pathogen Interactions, Virulence, and Ciprofloxacin Susceptibility of Alford MA; Baquir B; An A; Choi KG; Hancock REW Front Cell Infect Microbiol; 2021; 11():694789. PubMed ID: 34249781 [No Abstract] [Full Text] [Related]
19. Diversification of Pseudomonas aeruginosa within the cystic fibrosis lung and its effects on antibiotic resistance. Clark ST; Guttman DS; Hwang DM FEMS Microbiol Lett; 2018 Mar; 365(6):. PubMed ID: 29401362 [TBL] [Abstract][Full Text] [Related]
20. Genetic determinants of virulence and antibiotic resistance are common for Pseudomonas aeruginosa ST235 isolates from cystic fibrosis patients from various geographical regions. Savinova T; Bocharova Y; Mayanskiy N; Chebotar I Diagn Microbiol Infect Dis; 2022 Mar; 102(3):115596. PubMed ID: 34902620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]